AstraZeneca plc (AZN) Given Consensus Rating of “Hold” by Analysts

AstraZeneca plc (NYSE:AZN) has been given an average rating of “Hold” by the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $39.50.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, June 29th. ValuEngine downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Morningstar restated a “hold” rating on shares of AstraZeneca in a research report on Tuesday, June 12th. Finally, Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th.

Several hedge funds and other institutional investors have recently modified their holdings of AZN. Neuberger Berman Group LLC lifted its position in shares of AstraZeneca by 6.7% during the 1st quarter. Neuberger Berman Group LLC now owns 196,890 shares of the company’s stock valued at $6,885,000 after acquiring an additional 12,339 shares during the period. Northern Trust Corp lifted its position in shares of AstraZeneca by 4.9% during the 1st quarter. Northern Trust Corp now owns 2,388,024 shares of the company’s stock valued at $83,509,000 after acquiring an additional 111,911 shares during the period. BlackRock Inc. lifted its position in shares of AstraZeneca by 3.9% during the 1st quarter. BlackRock Inc. now owns 6,626,120 shares of the company’s stock valued at $231,715,000 after acquiring an additional 248,598 shares during the period. Brinker Capital Inc. lifted its position in shares of AstraZeneca by 8.9% during the 1st quarter. Brinker Capital Inc. now owns 35,730 shares of the company’s stock valued at $1,249,000 after acquiring an additional 2,917 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of AstraZeneca by 6.7% during the 1st quarter. JPMorgan Chase & Co. now owns 183,270 shares of the company’s stock valued at $6,409,000 after acquiring an additional 11,514 shares during the period. Hedge funds and other institutional investors own 15.97% of the company’s stock.

NYSE:AZN traded up $0.57 during mid-day trading on Thursday, hitting $39.65. 166,255 shares of the company’s stock were exchanged, compared to its average volume of 3,232,180. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.72 and a quick ratio of 0.54. AstraZeneca has a fifty-two week low of $31.99 and a fifty-two week high of $39.76. The company has a market cap of $98.00 billion, a PE ratio of 9.26, a P/E/G ratio of 2.05 and a beta of 0.60.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.38. The firm had revenue of $5.16 billion for the quarter, compared to the consensus estimate of $5.09 billion. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.87 EPS. equities research analysts expect that AstraZeneca will post 1.68 EPS for the current year.

The company also recently declared a semiannual dividend, which was paid on Monday, September 10th. Stockholders of record on Friday, August 10th were given a $0.45 dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a dividend yield of 2.35%. AstraZeneca’s dividend payout ratio (DPR) is currently 20.56%.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply